Doxorubicin or daunorubicin given upfront in a therapeutic window are equally effective in children with newly diagnosed acute lymphoblastic leukemia. A randomized comparison in trial CoALL 07-03

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 254-257

  Escherich, Gabriele ^a   Zimmermann, Martin ^b   Janka Schaub, Gritta ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute lymphoblastic leukemia; Anthracycline; Efficacy

Indexed keywords

DAUNORUBICIN; DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD; CANCER DIAGNOSIS; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; INFECTION; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84871171498     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24273     Document Type: Article

References (22)

1. Holton CP, Lonsdale D, Nora AH, et al. Clinical study of daunomycin (NSC-82151) in children with acute leukemia. Cancer 1968;22:1014-1017.
2. Holton CP, Vietti TJ, Nora AH, et al. Clinical study of daunomycin and prednisone for induction of remission in children with advanced leukemia. N Engl J Med 1969;280:171-174.
3. Tatsumi K, Nakamura T, Wakisaka G. Comparative effect of daunomycin and adriamycin on nucleic acid metabolism in leukemic cells in vitro. Gann 1974;65:237-247.
4. Tan C, Tasaka H, Yu KP, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967;20:333-353.
5. Buick RN, Messner HA, Till JE, et al. Cytotoxicity of adriamycin and daunorubicin for normal and leukemia progenitor cells of man. J Natl Cancer Inst 1979;62:249-255.
6. Wang JJ, Chervinsky DS, Rosen JM. Comparative biochemical studies of adriamycin and daunomycin in leukemic cells. Cancer Res 1972;32:511-515.
7. Kaspers GL, Veerman AJ, Pieters R, et al. In vitro cytotoxicity of mitoxantrone, daunorubicin and doxorubicin in untreated childhood acute leukemia. Leukemia 1994;8:24-29.
8. Bielack SS, Kallenbach K, Looft G, et al. Structurally modified anthracyclines retain activity in a cell line with simultaneous typical and atypical multidrug resistance. Anticancer Res 1995;15:1279-1284.
9. Schwartz HS, Grindey GB. Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 1973;33:1837-1844.
10. Razek A, Valeriote F, Vietti T. Survival of hematopoietic and leukemic colony-forming cells in vivo following the administration of daunorubicin or adriamycin. Cancer Res 1972;32:1496-1500.
11. Sandberg JS, Howsden FL, DiMarco A, et al. Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151). Cancer Chemother Rep 1970;54:1-7.
12. Tan C, Etcubanas E, Wollner N, et al. Adriamycin-An antitumor antibiotic in the treatment of neoplastic diseases. Cancer 1973;32:9-17.
13. Sallan SE, Camitta BM, Frei E 3rd, et al. Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): Addition of an anthracycline to vincristine and prednisone. Med Pediatr Oncol 1977;3:281-287.
14. Graubner UB, Porzig S, Jorch N, et al. Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2007;50:259-263.
15. Hodges JL, Jr., Lehmann EL. "Hodges-Lehmann estimators, "in: S, Kotz NL, Johnson CB, Read editors Encyclopedia of statistical sciences. Vol. 3. New York: John Wiley & Sons; 1983. pp. 463-465.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: Wiley; 2002.
18. Escherich G, Göbel U, Jorch N, et al. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: A randomized comparison in children with newly diagnosed acute lymphoblastic leukemia. Klin Padiatr 2007;219:134-138.
19. Riehm H, Reiter A, Schrappe M, et al. Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klin Padiatr 1987;199:151-160.
20. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-1738.
21. Zhou J, Goldwasser MA, Li A, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01. Blood 2007;110:1607-1611.
22. zur Stadt U, Harms DO, Schlüter S, et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: Outcome prediction strongly depends on the therapeutic regimen. Leukemia 2001;15:283-285.